Loading…
Women and Minority Equity Investment Act of 2019
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 9,062 other HR bills in the 116th — cohort avg 39d
Women and Minority Equity Investment Act of 2019 This bill modifies eligibility requirements for Small Business Administration (SBA) contracting opportunities available to a woman- or minority-owned business. Currently, to be eligible for certain SBA programs, a woman or minority business owner must own an unconditional majority (at least 51%) of their business. However, the bill allows a woman- or minority-owned small business to maintain its contracting eligibility in the event a venture capital or private equity firm purchases an ownership stake in the business, so long as the purchasing enterprise is also owned by either a woman or minority.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (3)
2024 · fourth_quarter · Health Issues
H.R. 3, (117th Cong.) Elijah E. Cummings Lower Drug Costs Now Act H.R. 19, (117th Cong.) Lower Costs, More Cures Act of 2021 H.R. 830, Help Ensure Lower Patient (HELP) Copays Act H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 2679, Pharmacy Benefits Manager Accountability Act H.R. 2691, Transparent Prices Required to Inform Consumer and Employers (Transparent PRICE) Act H.R. 2816, Pharmacy Benefit Manager Sunshine and Accountability Act H.R. 2880, Protecting Patients Against PBM Abuses Act H.R. 2940/S. 1355, Pioneering Antimicrobial Subscriptions to End Upsurging Resistance Act (PASTEUR) Act of 2023 H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program H.R. 3285, Fairness for Patient Medications Act H.R. 3633, PREVENT HPV Cancers Act of 2023 H.R. 4368/S. 2131, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024 H.R. 4895, Lowering Drug Costs for American Families Act H.R. 5376/S. 2474, Share the Savings with Seniors Act H.R. 6283, Delinking Revenue from Unfair Gouging (DRUG) Act H.R. 7174, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 7635, The 340B PATIENTS Act of 2024 H.R. 8467, Farm, Food, and National Security Act of 2024 S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1339, Pharmacy Benefit Manager Reform Act S. 1895 (116th Congress) Lower Health Care Costs Act S. 2333, Pandemic and All-Hazards Preparedness and Response Act S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 S. 4229, Reducing Drug Prices for Seniors Act. Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Anti-microbial Resistance; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines catch up; Vaccines issues; Package inserts, labeling issues, and E-Labeling authorization legislation; Pharmaceutical Supply Channel issues; Drug shortage issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; Issues related to the Patent and Trademark Law Amendments Act (PL 96-517); FY-2024 Budget and Appropriations Legislation; Intellectual property protection and trade issues; WTO IP Waiver for COVID therapeutics Animal Health; Animal Health Technology Issues; National Institute of Standards and Technology (NIST) draft Interagency Guidance Framework for Considering the Exercise of March-In Rights Animal Health Policy Issues: ADUFA & Funding for Electronic Animal Traceability; One Health Issues; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues.
Referred to the House Committee on Small Business.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $1,800,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2024 · fourth_quarter · Health Issues
H.R. 3, (117th Cong.) Elijah E. Cummings Lower Drug Costs Now Act H.R. 19, (117th Cong.) Lower Costs, More Cures Act of 2021 H.R. 830, Help Ensure Lower Patient (HELP) Copays Act H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 2679, Pharmacy Benefits Manager Accountability Act H.R. 2691, Transparent Prices Required to Inform Consumer and Employers (Transparent PRICE) Act H.R. 2816, Pharmacy Benefit Manager Sunshine and Accountability Act H.R. 2880, Protecting Patients Against PBM Abuses Act H.R. 2940/S. 1355, Pioneering Antimicrobial Subscriptions to End Upsurging Resistance Act (PASTEUR) Act of 2023 H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program H.R. 3285, Fairness for Patient Medications Act H.R. 3633, PREVENT HPV Cancers Act of 2023 H.R. 4368/S. 2131, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024 H.R. 4895, Lowering Drug Costs for American Families Act H.R. 5376/S. 2474, Share the Savings with Seniors Act H.R. 6283, Delinking Revenue from Unfair Gouging (DRUG) Act H.R. 7174, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 7635, The 340B PATIENTS Act of 2024 H.R. 8467, Farm, Food, and National Security Act of 2024 S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1339, Pharmacy Benefit Manager Reform Act S. 1895 (116th Congress) Lower Health Care Costs Act S. 2333, Pandemic and All-Hazards Preparedness and Response Act S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 S. 4229, Reducing Drug Prices for Seniors Act. Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Anti-microbial Resistance; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines catch up; Vaccines issues; Package inserts, labeling issues, and E-Labeling authorization legislation; Pharmaceutical Supply Channel issues; Drug shortage issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; Issues related to the Patent and Trademark Law Amendments Act (PL 96-517); FY-2024 Budget and Appropriations Legislation; Intellectual property protection and trade issues; WTO IP Waiver for COVID therapeutics Animal Health; Animal Health Technology Issues; National Institute of Standards and Technology (NIST) draft Interagency Guidance Framework for Considering the Exercise of March-In Rights Animal Health Policy Issues: ADUFA & Funding for Electronic Animal Traceability; One Health Issues; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues.
Client expense: $1,730,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2024 · third_quarter · Health Issues
H.R. 3, (117th Cong.) Elijah E. Cummings Lower Drug Costs Now Act H.R. 19, (117th Cong.) Lower Costs, More Cures Act of 2021 H.R. 830, Help Ensure Lower Patient (HELP) Copays Act H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 2679, Pharmacy Benefits Manager Accountability Act H.R. 2691, Transparent Prices Required to Inform Consumer and Employers (Transparent PRICE) Act H.R. 2816, Pharmacy Benefit Manager Sunshine and Accountability Act H.R. 2880, Protecting Patients Against PBM Abuses Act H.R. 2940/S. 1355, Pioneering Antimicrobial Subscriptions to End Upsurging Resistance Act (PASTEUR) Act of 2023 H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program H.R. 3285, Fairness for Patient Medications Act H.R. 3633, PREVENT HPV Cancers Act of 2023 H.R. 4368/S. 2131, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024 H.R. 4895, Lowering Drug Costs for American Families Act H.R. 5376/S. 2474, Share the Savings with Seniors Act H.R. 6283, Delinking Revenue from Unfair Gouging (DRUG) Act H.R. 7174, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 7635, The 340B PATIENTS Act of 2024 H.R. 8467, Farm, Food, and National Security Act of 2024 S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1339, Pharmacy Benefit Manager Reform Act S. 1895 (116th Congress) Lower Health Care Costs Act S. 2333, Pandemic and All-Hazards Preparedness and Response Act S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 S. 4229, Reducing Drug Prices for Seniors Act. Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Anti-microbial Resistance; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines catch up; Vaccines issues; Package inserts, labeling issues, and E-Labeling authorization legislation; Pharmaceutical Supply Channel issues; Drug shortage issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; Issues related to the Patent and Trademark Law Amendments Act (PL 96-517); FY-2024 Budget and Appropriations Legislation; Intellectual property protection and trade issues; WTO IP Waiver for COVID therapeutics Animal Health; Animal Health Technology Issues; National Institute of Standards and Technology (NIST) draft Interagency Guidance Framework for Considering the Exercise of March-In Rights Animal Health Policy Issues: ADUFA & Funding for Electronic Animal Traceability; One Health Issues; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues.
Client expense: $2,190,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · second_quarter · Health Issues
H.R. 3, (117th Cong.) Elijah E. Cummings Lower Drug Costs Now Act H.R. 19, (117th Cong.) Lower Costs, More Cures Act of 2021 H.R. 830, Help Ensure Lower Patient (HELP) Copays Act H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 2679, Pharmacy Benefits Manager Accountability Act H.R. 2691, Transparent Prices Required to Inform Consumer and Employers (Transparent PRICE) Act H.R. 2816, Pharmacy Benefit Manager Sunshine and Accountability Act H.R. 2880, Protecting Patients Against PBM Abuses Act H.R. 2940/S. 1355, Pioneering Antimicrobial Subscriptions to End Upsurging Resistance Act (PASTEUR) Act of 2023 H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program H.R. 3285, Fairness for Patient Medications Act H.R. 3633, PREVENT HPV Cancers Act of 2023 H.R. 4368/S. 2131, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024 H.R. 4895, Lowering Drug Costs for American Families Act H.R. 5376/S. 2474, Share the Savings with Seniors Act H.R. 6283, Delinking Revenue from Unfair Gouging (DRUG) Act H.R. 7174, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 7635, The 340B PATIENTS Act of 2024 H.R. 8467, Farm, Food, and National Security Act of 2024 S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1339, Pharmacy Benefit Manager Reform Act S. 1895 (116th Congress) Lower Health Care Costs Act S. 2333, Pandemic and All-Hazards Preparedness and Response Act S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 S. 4229, Reducing Drug Prices for Seniors Act. Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Anti-microbial Resistance; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines catch up; Vaccines issues; Package inserts, labeling issues, and E-Labeling authorization legislation; Pharmaceutical Supply Channel issues; Drug shortage issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; Issues related to the Patent and Trademark Law Amendments Act (PL 96-517); FY-2024 Budget and Appropriations Legislation; Intellectual property protection and trade issues; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; WTO IP Waiver for COVID therapeutics Animal Health; Animal Health Technology Issues; National Institute of Standards and Technology (NIST) draft Interagency Guidance Framework for Considering the Exercise of March-In Rights Animal Health Policy Issues: ADUFA & Funding for Electronic Animal Traceability; One Health Issues; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues.
Client expense: $3,010,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · first_quarter · Health Issues
H.R. 3, (117th Cong.) Elijah E. Cummings Lower Drug Costs Now Act H.R. 19, (117th Cong.) Lower Costs, More Cures Act of 2021 H.R. 830, Help Ensure Lower Patient (HELP) Copays Act H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 2679, Pharmacy Benefits Manager Accountability Act H.R. 2691, Transparent Prices Required to Inform Consumer and Employers (Transparent PRICE) Act H.R. 2816, Pharmacy Benefit Manager Sunshine and Accountability Act H.R. 2880, Protecting Patients Against PBM Abuses Act H.R. 2940/S. 1355, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance Act (PASTEUR) Act of 2023 H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program H.R. 3285, Fairness for Patient Medications Act H.R. 3633, PREVENT HPV Cancers Act of 2023 H.R. 4368/S. 2131, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024 H.R. 4895, Lowering Drug Costs for American Families Act H.R. 5376/S. 2474, Share the Savings with Seniors Act H.R. 6283, Delinking Revenue from Unfair Gouging (DRUG) Act H.R. 7174, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 7635, The 340B PATIENTS Act of 2024 S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1339, Pharmacy Benefit Manager Reform Act S. 1895 (116th Congress) Lower Health Care Costs Act S. 2333, Pandemic and All-Hazards Preparedness and Response Act S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Anti-microbial Resistance; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines catch up; Vaccines issues; Package inserts, labeling issues, and E-Labeling authorization legislation; Pharmaceutical Supply Channel issues; Drug shortage issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; Issues related to the Patent and Trademark Law Amendments Act (PL 96-517); FY-2024 Budget and Appropriations Legislation; Intellectual property protection and trade issues; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; WTO IP Waiver for COVID therapeutics Animal Health; Animal Health Technology Issues; Animal Health Policy Issues: ADUFA & Funding for Electronic Animal Traceability; One Health Issues; General pharmaceutical issues; Farm Bill 2023; Vaccine Injury Compensation Program (VICP); Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms.
Client expense: $2,190,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · first_quarter · Small Business
Issues relating to entrepreneurship, including government regulations, taxation, cloud computing, veteran-owned businesses, security and access to credit - SBA Reauthorization and Improvement Act of 2019 (unnumbered). Issues relating to creating a "one-stop-shop" for entrepreneurs to engage with federal, state and local governments - no specific legislation. Issues related to sole-sourcing and parity for small businesses - no specific legislation. Issues related to women-owned business access to 8A venture capital funds - S. 1981, H.R. 3633, Women and Minority Equity Investment Act of 2019. Efforts to create a tri-state, bi-national business incubator - no specific legislation. Efforts to support small business response to COVID-19: H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; H.R. 6201, Families First Coronavirus Response Act; H.R. 748, Coronavirus Aid, Relief, and Economic Security (CARES) Act.
Client expense: $920,000 · Firm income: Not reported
2019 · fourth_quarter · Small Business
Issues relating to entrepreneurship, including government regulations, taxation, cloud computing, veteran-owned businesses, security and access to credit - SBA Reauthorization and Improvement Act of 2019 (unnumbered). Issues relating to creating a "one-stop-shop" for entrepreneurs to engage with federal, state and local governments - no specific legislation. Efforts to allow entrepreneurs to incubate in surplus government office buildings or agency office space - no specific legislation. Issues related to sole-sourcing and parity for small businesses - no specific legislation. Issues related to small batch manufacturing - no specific legislation. Issues related to women-owned business access to 8A venture capital funds - S. 1981, H.R. 3633, Women and Minority Equity Investment Act of 2019. Efforts to create a tri-state, bi-national business incubator - no specific legislation.
Client expense: $1,060,000 · Firm income: Not reported
2019 · fourth_quarter · Small Business
Small Business Act reauthorization (SBA Federal Procurement Programs -Woman-Owned Small Business Program; Access to Capital for Woman-Owned Small Businesses: Women and Minority Equity Investment Act, H.R. 3633, S. 1981; Small Business Saturday Resolution H.Res. 730
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2019 · third_quarter · Small Business
Small Business Act reauthorization (SBA Federal Procurement Programs -Woman-Owned Small Business Program; Sole Source Parity for the Woman-Owned Small Business Program: Expanding Contracting Opportunities for Small Business Act, H.R. 190; Access to Capital for Woman-Owned Small Businesses: Women and Minority Equity Investment Act, H.R. 3633, S. 1981
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: Air Force, Dept of, Commerce, Dept of (DOC), Executive Office of the President (EOP), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
Government targets: Air Force, Dept of, Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office